ClinicalTrials.gov
public full text
Public Domain
sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
The primary objective is to determine the clinical efficacy of treatment regimen in terms of objective response rate (ORR). The secondary objectives is to determine the clinical efficacy of the study treatment in terms of progression free survival (PFS) and overall survival (OS). Additionally, to characterize the safety and toxicity profile of the study treatment as measured by the adverse event rates.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial#981753
- Varenicline In-Patient Study#1086693
- Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy.#837527
- Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients#1319904
- Early Palliative Care in Metastatic Esophageal Squamous Carcinoma (ESCC) and Gastric Cancer#1140758
Record · ID 1349856
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive